Want to see ACHV full AI Analyst Report?
ACHV Stock Chart & Stats
$5.10
-$0.11(-3.08%)
At close: 4:00 PM EST
$5.10
-$0.11(-3.08%)
Day’s Range― - ―
52-Week Range$2.02 - $7.11
Previous CloseN/A
Volume131.37K
Average Volume (3M)1.65M
Market Cap
$657.02M
Enterprise Value$537.13M
Total Cash (Recent Filing)$29.27M
Total Debt (Recent Filing)$14.95M
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Aug 06, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding102,659,060
10 Day Avg. Volume2,061,462
30 Day Avg. Volume1,650,824
Financial Highlights & Ratios
PEG Ratio-4.93
Price to Book (P/B)10.07
Price to Sales (P/S)0.00
P/FCF Ratio-4.38
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.24K
Enterprise Value/Ebitda-10.56
Forecast
1Y Price Target
$14.33Price Target Upside181.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Phase III Efficacy In Hard-to-treat SmokersConsistently strong Phase III efficacy, including large absolute and odds-ratio benefits in prior-treatment subgroups, supports durable clinical differentiation versus existing therapies. This efficacy underpins long-term commercial adoption, formulary interest, and physician prescribing if approved.
Transformational Financing Strengthens RunwayA sizable $180M upfront capital raise with significant warrant upside meaningfully extends funding for resubmission, manufacturing transfer, Phase III vaping study and commercialization planning. This reduces short-term liquidity pressure and enables execution toward a planned launch.
Onshore Manufacturing Partnership With Initial Engineering BatchShifting primary manufacturing to a U.S. partner and completing an engineering batch represents a durable operational improvement—reducing import/tariff and CGMP exposure and enabling scale-up. Successful tech transfer is foundational for reliable commercial supply.
Bears Say
Pre-commercial, No Product RevenueAbsent product revenue and persistent large net losses mean the business relies on external financing. This structural profile drives dilution risk, limited margin resilience, and sustained negative free cash flow until commercial sales materialize.
Rising Leverage And Weakened Equity BaseHigher leverage and a shrunken equity cushion reduce financial flexibility and increase vulnerability to execution hiccups. In a pre-revenue stage this heightens refinancing and covenant risks, constraining strategic optionality over the coming months.
Regulatory And Manufacturing Execution Risk After FDA CRLAn FDA CRL driven by a third-party OAI forces an NDA resubmission and manufacturing tech transfer, delaying approval and extending burn. Unclear resubmission class/timing raises durable execution risk, potentially delaying revenue and giving rivals time to act.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences’s price range in the past 12 months?
Achieve Life Sciences lowest stock price was $2.02 and its highest was $7.11 in the past 12 months.
What is Achieve Life Sciences’s market cap?
Achieve Life Sciences’s market cap is $657.02M.
When is Achieve Life Sciences’s upcoming earnings report date?
Achieve Life Sciences’s upcoming earnings report date is Aug 06, 2026 which is in 34 days.
How were Achieve Life Sciences’s earnings last quarter?
Achieve Life Sciences released its earnings results on May 12, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.299 by $0.109.
Is Achieve Life Sciences overvalued?
According to Wall Street analysts Achieve Life Sciences’s price is currently Undervalued.
Does Achieve Life Sciences pay dividends?
Achieve Life Sciences does not currently pay dividends.
What is Achieve Life Sciences’s EPS estimate?
Achieve Life Sciences’s EPS estimate is -0.16.
How many shares outstanding does Achieve Life Sciences have?
Achieve Life Sciences has 102,659,060 shares outstanding.
What happened to Achieve Life Sciences’s price movement after its last earnings report?
Achieve Life Sciences reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.299. Following the earnings report the stock price went up 7.156%.
Which hedge fund is a major shareholder of Achieve Life Sciences?
Currently, no hedge funds are holding shares in ACHV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Achieve Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (181.05% Upside)
$14.33 (181.05% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 42.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
188.28%
12-Months-Change
Fundamentals
Return on Equity
-193.49%
Trailing 12-Months
Asset Growth
21.01%
Trailing 12-Months
Company Description
Achieve Life Sciences
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
ACHV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: a substantial financing, experienced new leadership and commercial hires, U.S. manufacturing partnership with initial batches, robust Phase III efficacy (notably 32.4% vs 6% in hard-to-treat patients) and supportive mechanistic/tolerability data. The principal negatives are an anticipated FDA CRL tied to a third-party manufacturer OAI, requiring an NDA resubmission in Q4 2026 and introducing execution risk around the manufacturing tech transfer to Adare and timing uncertainty. Overall, the company appears well capitalized and operationally proactive to address the delays and pursue a planned H1 2027 launch, but near-term regulatory and manufacturing execution risks remain.View all ACHV earnings summariesACHV Stock 12 Month Forecast
Average Price Target
$14.33
▲(181.05% Upside)
Technical Analysis
Ownership Overview
0.87% Insiders
4.25% Mutual Funds
7.02% Other Institutional Investors
79.59% Public Companies and
Individual Investors